PDCD1 and lung carcinoma: As the most successful representative of immunotherapy, programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) inhibitor had shown better performance over conventional chemotherapy in terms of OS, response rate, and progression-free survival (PFS) for the treatment of lung cancer [10, 11].